Helper-dependent adenovirus vectors (HDVs) are safe and efficient tools for gene transfer with high cloning capacity. However, the multiple amplification steps needed to produce HDVs hamper a robust production process and in turn the availability of high-quality vectors. To understand the factors behind the low productivity, we analyzed the progression of HDV life cycle. Canine adenovirus (Ad) type 2 vectors, holding attractive features to overcome immunogenic concerns and treat neurobiological disorders, were the focus of this work. When compared with E1-deleted (ΔE1) vectors, we found a faster helper genome replication during HDV production. This was consistent with an upregulation of the Ad polymerase and pre-terminal protein and led to higher and earlier expression of structural proteins. Although genome packaging occurred similarly to ΔE1 vectors, more immature capsids were obtained during HDV production, which led to a~4-fold increase in physical-to-infectious particles ratio. The higher viral protein content in HDV-producing cells was also consistent with an increased activation of autophagy and cell death, in which earlier cell death compromised volumetric productivity. The increased empty capsids and earlier cell death found in HDV production may partially contribute to the lower vector infectivity. However, an HDV-specific factor responsible for a defective maturation process should be also involved to fully explain the low infectious titers. This study showed how a deregulated Ad cycle progression affected cell line homeostasis and HDV propagation, highlighting the impact of vector genome design on virus-cell interaction.
INTRODUCTION
Adenoviruses (Ads) are non-enveloped, icosahedral particles containing a linear, double-stranded DNA genome. Ad vectors have received considerable attention as gene transfer tools in which human Ad serotype 5 is the typical prototype vector backbone. However, the hurdles facing the clinical use of human adenoviral vectors, including innate and pre-existing immunity, may limit the efficiency and time of transgene expression. 1 One of the alternatives to circumvent these drawbacks is using nonhuman Ads, such as canine adenovirus type 2 (CAV-2) vectors. 2 In addition to the paucity of anti-CAV-2 neutralizing antibodies in humans, 2,3 their vectors induce a low level of innate response and no activation of human complement pathways. 4, 5 Their ability to preferentially transduce neurons, combined with a remarkable capacity of axonal transport, 6,7 make CAV-2 vectors promising candidates for the treatment of neurodegenerative diseases. 8, 9 Ad genome has been progressively modified from the wild-type to improve vector safety and efficacy in therapeutic applications (reviewed elsewhere Dormond et al. 10 ). Helper-dependent vectors (HDVs), devoid of viral coding regions, are powerful tools for gene transfer in vivo. HDVs combine high transduction efficacies, longterm gene expression and a cloning capacity of 430 kb. These vectors retain only on their genomes the inverted terminal repeats, the packaging region (Ψ) and an expression cassette(s). To produce HDVs, both early and late viral functions need to be complemented in a synchronized manner. Standard production methods are based on the co-infection of E1-transcomplementing cells with HDV and an E1-deleted helper vector (HV), which provides the viral proteins in trans. During production, both HDV and HV genomes replicate inside the cells, but the encapsidation of the HV genome is minimized, by flanking its Ψ with recognition sequences for a recombinase constitutively expressed by the cells, such as FLP 11, 12 or Cre. 13 Despite their enormous potential, the use of HDVs in preclinical and clinical settings is limited because of two bottlenecks: contamination with HV and production yields. Several efforts to reduce HV contamination have been described. Based on alternative vector designs, deletion of the Ψ in the HV genome was improved through the development of an inducible selfinactivating vector (vector expressing a recombinase that can block its own genome packaging). 14 Moreover, tweaking the HV packaging domain can delay its packaging, 15 or reduce its packaging efficiency in co-infection contexts. 16, 17 Reduced HDV production obtained after the initial transfection step, limited by transfection efficiency and initiation of viral DNA replication from plasmid substrates, has also prompted others to improve the strategies. With a focus on this step, production of HDV was improved by creating cell lines expressing pre-terminal protein and adenoviral DNA polymerase, 18 optimizing transfection methods compliant with scalable processes 9 and developing an intracellular system to release HDV genome from transfected circular plasmids, which increased transfection efficiencies of 10-fold. 20 However, even under improved conditions, multiple amplification steps are needed to rescue HDV amplification to its maximum and prepare sufficient quantities of vector. 14, 19, 21, 22 Moreover, most reports show a relatively low infectivity of HDV in comparison with physical particles (PPs; optical density based) titers 14, 23 and, equally importantly, inconsistent infectious yields obtained in different preparations of the same HDV. 14 Although most studies were conducted with human HDVs, consistently low infectious titers are also extended to canine HDVs. 4, 6, 9 Ads have a regulated infection cycle where multiple viral and cellular proteins interact to enable a productive virus replication and generate infectious virus particles (reviewed in Flint et al. 24 ). Therefore, understanding the Ad replication steps during the generation of HDV particles could help break the bottlenecks behind the productivity of these vectors. After cell binding, the mature viral particle is internalized and transported toward the nucleus. During this transport, the particle is dismantled by an ordered elimination of some structural proteins and culminates with the delivery of the viral genome into the nucleus via nuclear pore complexes. 25 Once in the nucleus, early genes are expressed and viral DNA replication starts. Late phase of infection is then activated and structural proteins expressed. These proteins are likely assembled into empty virions, followed by the packaging of viral genome. Finally, viral particles undergo a protease-mediated maturation process to becomes infectious. [26] [27] [28] In this study, we investigated the steps of Ad cycle that could be affected during HD CAV-2 production. As CAV-2 vectors use keeps increasing, 8, 9 larger amounts of high-quality vectors to conduct preclinical and possibly clinical assays are required. Therefore, understanding HDV productivity is critical to identify and hopefully overcome the manufacturing limitations. Here, we provide evidences of a distinct replication cycle progression during HDV production, which resulted in changes in the cell physiology and vector productivity.
RESULTS
We initially asked whether the limitations in HDVs production were related to differences in Ad propagation kinetics. To address this possibility, HD CAVGFP production was characterized and the main steps of Ad life cycle were evaluated by comparing it with CAVGFP (an E1-deleted vector) and JBΔ5 (a HV containing a loxP flanked packaging domain). Figure 1 depicts the experimental design used in this study ( Figure 1a ) and the relevant characteristics of each vector ( Figure 1b ). CAVGFP (herein designated as ΔE1), harboring the same enhanced green fluorescent protein (GFP) expression cassette as HD CAVGFP (herein designated as HDV), was used as the control. Moreover, considering that to produce HDV, cells are co-infected with HV, coinfection with HV JBΔ5 was also performed in the ΔE1 production control assays. Finally, the propagation of HV alone was also performed. Thus, three infections/production scenarios in Creexpressing cells were analyzed: (i) HDV co-infected with HV (HDV +HV), (ii) ΔE1 co-infected with HV (ΔE1+HV) and (iii) HV.
Volumetric productivity and viral particles infectivity are impaired in HDV production To determine the productivities of HDV, production assays with HDV+HV, ΔE1+HV and HV alone were performed ( Figure 1a ). Vectors were harvested 48 hours post infection (h.p.i.) and quantified for PPs (genome-containing capsids) and infectious particles (IPs) ( Figure 2 ). We found a similar cell-specific production of PPs for both HDV and ΔE1 vectors (Figure 2a ). However, fewer infectious HDV particles were detected. Concomitantly, similar PP/cell of HV was obtained in the three infection schemes, but at a lower number of IP in HDV+HVproducing profile (Figures 1a-i and 2b). From 24 h.p.i. onward, the viability of HDV+HV-producing cells was half of that obtained for both control infections (Figure 2c ), which likely affected the volumetric productivity ( Figure 2d ).
Cell binding and trafficking into the nucleus does not affect HDV production As mentioned above, there are several steps in vector amplification. To address the capacity of binding, trafficking and genome delivery of HDV, the progression of infection was monitored in extracellular and intracellular fractions. The decrease of extracellular vector concentration (that is, culture medium) typically occurs during the first 24 h.p.i. 29 and can be used to quantify binding and/or internalization. In parallel, intracellular genome genome construct that should be considered in each infection scheme. The amplification of HDV was analyzed by comparison with ΔE1 and HV, and three infection/production assays were performed: (i) HDV, (ii) ΔE1 (which share same expression cassette than HDV), and (iii) HV. The production of HDV requires co-infection of HDV and HV. As a control of co-infection, ΔE1 assays were performed by co-infecting producer cells with HV. To isolate the role of HV, the third group of production assays was performed by infecting producer cells with only HV. HDV or ΔE1 production assays mentioned throughout the text correspond to (i) HDV+HV or (ii) ΔE1+HV co-infections, respectively. MDCK-E1-Cre cells were used as producer cells and infected using MOI 5 of HDV and ΔE1 and MOI 1 of HV. Ψ, packaging sequence. accumulation can be accurately measured until the vector replication starts at approximately 8 h.p.i.
To evaluate the extracellular fraction, IPs during HDV+HV production were quantified from culture medium at 0, 12 and 24 h.p.i. and the profiles were compared with ΔE1+HV production. We found that the profiles of HDV and ΔE1 vectors were similar (Figure 3a ), which suggests that the ability to bind cells was maintained in HDV.
The progression from binding to internalization and trafficking was evaluated by quantifying viral genomes from intracellular fractions collected at 3, 6 and 9 h.p.i. in the three infection scenarios (Figure 1a ). To analyze vector genomes reaching nucleus, nuclear extracts were collected 8 h.p.i. We found that the intracellular accumulation of vector genomes was similar for HDV and ΔE1 at the three time points ( Figure 3b ). Also, we found similar levels of HDV and ΔE1 viral genomes in nuclear extracts (Figure 3c ), indicating that these steps were not affected during HDV+HV production. To complement these assays, the intracellular accumulation of HV genomes was also evaluated. We found similar intracellular HV genomes at 3 and 6 h.p.i. in all production schemes. However, a slight increase in HV genomes in HDV+HVproducing cells compared with ΔE1+HV and HV productions was observed at 9 h.p.i. (Figure 3d ). As vector genome replication starts at~8 h.p.i., this observation may be connected to differences in HV genome replication in HDV+HV production scenario, rather than to the capacity to infect cells.
Replication of vector genome increases in HDV-producing cells
After the delivery of viral genomes into the nucleus, transcription of early region gene products and viral DNA replication are the subsequent steps in Ad propagation. To analyze whether viral DNA replication was altered in HDV+HV-producing cells, intracellular viral genomes were quantified from 12 to 48 h.p.i. (Figure 4 ). Similar quantities of vector genomes were obtained in the three vector production scenarios at 48 h.p.i. (Figures 4a and b ). However, the quantity of HV genomes in HDV+HV-producing cells (scenario (i) from Figure 1a ) was higher from 12 to 24 h.p.i., especially at 15 h.p.i.: increases of a 10-and 71-fold were observed when compared with ΔE1+HV − and HV-producing cells, respectively ( Figure 4b ). These data indicated that HV genome replication occurred faster in HDV +HV-producing cells.
The transgene expression in terms of mRNA was also evaluated as an indicator of transcription capacity because to some extent may represent the immediate-early transcription. These showed lower levels of GFP and slightly higher levels of β-galactosidase in HDV+HV-infected cells when compared with ΔE1+HV and HV infections (Supplementary Material Figure S1 ).
Expression of genes implicated in viral DNA replication and late phase is observed earlier in HDV-producing cells Although early-phase genes are primarily transcribed before genome replication and the corresponding mRNA is transcribed from the input genomes, late region transcription becomes robust once DNA replication starts. To analyze whether the expression of viral genes was altered during HDV production, transcription and translation were analyzed.
Transcription analysis was performed by determining mRNA levels from several regions to have representatives of the different infection phases. Table 1 describes the viral genes analyzed and the corresponding infection phase and biological role. Viral genes to be analyzed were selected according to two main criteria: choose at least two viral genes from early and late phases, and viral genes involved in processes that occurred differently during HDV production, namely those involved in DNA replication (E2 region) 30 and those involved in capsid maturation (protease and pVI). 28, 31 In addition, IVa2 was analyzed because of its role during mid-late phase in activating late region expression 32 and later as key factor in viral genome packaging. 33 Regardless of the phase, the expression of all viral genes increased from 12 to 48 h.p.i. ( Supplementary Table S2 ). Notably, we found earlier and higher levels of viral transcripts in HDV+HV-producing cells. To better understand the gene expression pattern and the corresponding percentage of each viral product in the different infections, gene expression values were further normalized to the overall expression at each time. After this normalization, the results showed the switch of expression pattern from early-phase (12 h.p.i.) to late-phase transcription (24 and 48 h.p.i.) (Supplementary Figure S2) . Also, at 24 and 48 h.p.i. the expression pattern was similar and thus proportional in the different infections scenarios. However, an over-representation of E2 (E2B), IVa2 and L3 gene expression was observed at 12 h.p.i. ( Figure 5 ) in HDV+HV-producing cells, when compared with ΔE1 +HV − and HV-producing cells. This indicates that, in addition to the viral genes involved in genome replication (adenoviral DNA polymerase and pre-terminal protein), 30 late-phase activator (IVa2) 32 and late genes (L3) were also differentially expressed during HDV production, earlier in infection.
To evaluate translation, western blot analysis was performed using rabbit sera that detects capsid proteins against cell extracts obtained at 12, 24 and 48 h.p.i. In accordance to transcription analysis, the results showed that higher production of viral proteins was obtained earlier during HDV+HV production ( Figure 6 ).
Despite more assembled particles during HDV production, packaging occurs similarly to ΔE1 control Once the translation of late region transcripts is accomplished, the structural proteins are assembled into capsids and genomes are packaged to generate full virions. However, when producing Ad vectors, two types of viral particles are routinely produced: assembled genome-containing or empty capsids, which are assembled particles with little or no viral genome. 34 Therefore, to understand the type of particles generated during HDV production, assembly and packaging were further analyzed.
Assembly was analyzed by quantifying the assembled viral particles obtained 48 h.p.i. using the NanoSight technology, which measured assembled particles, the sum of empty capsids and full virions. In addition to a positive correlation between the number of assembled viral particles and viral proteins expression in each infection ( Figure 6 ), we found more assembled viral particles in HDV+HV production ( Figure 7a ).
Genome packaging was evaluated by comparing free viral genomes with total viral genomes (free genomes plus packaged genomes) at 48 h.p.i. To do so, viral DNA was extracted from intracellular samples in duplicate, in which one replicate was subjected to benzonase treatment prior DNA extraction; the decrease of quantified viral genomes in the samples treated with benzonase before DNA extraction, in comparison with non-treated sample, indicates the presence of free viral genomes. We found no significant changes in the free viral genomes obtained in HDV+HV − and ΔE1+HV-producing cells (Figure 7b ). By comparison, the quantity of HV-free viral genomes was similar in the three infection schemes. More free viral genomes should be obtained for HV than for HDV or ΔE1 vectors, as Cre recombinase specifically impacts HV genome packaging. This observation was not clear in Figure 7b , probably because of the considerable inter-assay variability (depicted by the error bars) that disguised the expected differences between free genomes percentage of HV and HDV or ΔE1 vector.
Together, these results showed that despite more viral capsids generated, the percentage of packaged HDV genomes did not increased. Notably, the total DNA of HDV and ΔE1 were similar at 48 h.p.i. (Figure 4a ).
Low cell viability during HDV production is linked to activation of autophagy and high levels of viral proteins affecting virus infectivity When compared with non-infected cells, a 3.32 ± 0.23-fold increase in necrotic cells was obtained at 24 h.p.i. during HDV production, versus 1.74 ± 0.15 and 1.42 ± 0.01 for ΔE1 and HV, respectively, which is consistent with the cell viability analysis (Figure 2d ). To further understand the cell death during HDV production, we evaluated the effect of HDV infection on cell viability, the activation of autophagy, an Ad-related programmed cell death, 35, 36 and the role of virus cycle progression on producer cells viability and viral productive outcome.
To determine the effect of infection on cell death, HDV infections were performed in MDCK-E1-Cre cells and MDCK cells at same multiplicity of infection (MOI) (Figure 1a -i), which do not express the CAV-2 E1 region and are therefore unable to allow productive infectious cycle of ΔE1 CAV-2 vectors. At 48 h.p.i., MDCK cell viability was maintained, indicating that HDV transduction (binding, trafficking and delivery of vector genome to the nucleus) per se did not induce cell death (data not shown).
The decay in cell viability (Figure 2c ) should be connected to an Ad-specific programmed cell death. Autophagy, a form of programmed cell death induced by Ads, 35, 36 was therefore evaluated via the detection of LC3-incorporated autophagosomes. One of the major hallmarks of activation of autophagic process is the formation of cellular autophagosome puncta containing LC3-II. We found an increase in LC3-II autophagosomes in HDV+HVproducing cells (Figure 8 ). While HDV+HV-producing cells presented 16 ± 4% autophagy-positive cells, ΔE1+HV-producing cells presented 2 ± 1%, corresponding to an eightfold difference. HV-producing cells or mock-infected cells did not present detectable autophagosome-like structures in the six analyzed sections. Moreover, the number of autophagosomes per autophagy-positive cells was higher in cells producing HDV+HV (Figure 8 ). This indicates that autophagy was more strongly induced during the production of these vectors.
To determine if cell death was due to the viral cycle progression, the intracellular environment observed during HDV+HV production (high levels of HV genomes and viral proteins earlier in time) was induced during ΔE1 production by increasing the MOI of HV (Figure 9 ). Forty-eight h.p.i., cell concentration and viral proteins levels were determined. Consistent with an increase in viral proteins (Figure 9a ), we found a decrease in cell viability when the HDV+HV production scenario was pursued (Figure 9b ). Furthermore, to analyze the effect of this scenario on production of viral vectors, PP and IP were quantified in the above-mentioned assay (Figure 9b) . The results showed a relation between cell death and low viral particles infectivity (increase in PP:IP ratio). However, although a 1.7 ± 0.3-fold increase in PP:IP ratio of ΔE1 vectors was obtained when co-infecting cells with a HV MOI 40, fewer viable cells compared with those observed during HDV+HV production were observed. Moreover, even under these circumstances, the decrease in viral particles infectivity did not reach the fourfold change when comparing HDV with ΔE1 vectors (Figure 2a ). 
DISCUSSION
The production of HDVs presents two important bottlenecks: HV contamination and production yields. Several efforts toward the reduction of HV contamination [11] [12] [13] [14] [15] and the improvement of transfection step [18] [19] [20] have been described, however, less attention has been paid to the overall production of HDV. More specifically, as the interest in CAV-2 vectors for gene therapy increases, 8, 9 understanding canine HDV productivities is important to accomplish a consistent production system, streamline the bioprocess and debottleneck high-quality preparations.
Despite the difficulty in comparing the titers described in the literature, because of the use different protocols, vectors and samples purity, cell-specific productivity of HD CAV-2 vectors (~10 5 PPs per cell (Figure 2a) ) was similar to the production yields reported for human HDV. 14, 21, 22 On the other hand, a~4-fold decrease in IPs of HDV was observed when compared with ΔE1 control vectors (Figure 2a ). Canine HDV preparations with higher PP:IP ratios than those obtained with ΔE1 vectors, being already reported, 4, 9 were consistently obtained in our hands (data not shown). Some studies show a relatively high and/or inconsistent PP:IP ratios among different preparations of same human HDV. 14, 23 Special attention must be paid to this, as the PP:IP ratio of clinical grade Ads is limited by Food and Drug Administration. In addition, we found a reduction in HDV volumetric productivity related with an higher producer cell death (Figures 2c and d) .
To further understand the limitations in HDV amplification, we analyzed virus cycle during vectors production. We found that HDV has a distinct viral cycle progression, which impaired producer cell homeostasis and vector production and quality.
Despite similar internalization and nuclear delivery (Figure 3 ), a faster vector genome replication of HV from 9 h.p.i. onward was obtained during the co-infection of HDV+HV (Figures 3d and 4b) . Any HV-specific effect was ruled out because this was not observed in HV-producing cells (Figure 1a -iii). Although an increase in HV genome replication was observed during co-infection with ΔE1 vector production (Figure 1a -ii), HV genome replication was even faster in HDV+HV-producing cells (Figure 1a-i) . The viral proteins involved in Ad genome replication, DNA-binding protein, adenoviral DNA polymerase and pre-terminal protein belong to E2 transcription unit. 30 Indeed, an upregulation of subunit E2B products was observed in HDV-producing cells ( Figure 5 ), which was consistent with the replication profile of HV genome in these conditions. Why this increase occurred during HDV+HV production, and the mechanism behind this upregulation, is still not clear. First, the activation of early-phase transcription is amplified by E1 (E1A) expression. 37 However, no differences were detected in E1 levels in the different infections assayed in this work (data not shown). The mechanism behind the upregulation of E2B gene products appears to be specific, because this was not observed in E2A subunit, which share same promoter, or E4. Unlike HV, the replication profile of HDV genome was more modest and in accordance with that obtained in ΔE1 control vector infection (Figure 4a ). Assuming that genome replication was upregulated in HDV+HV-producing cells, this may indicate that the stuffer sequence, besides affecting transgene expression (Supplementary Figure S1 ) as previously described, 38, 39 may impact HDV genome replication.
Faster HV genome replication contributed to an increase in expression of viral products, namely IVa2 and late-phase proteins (Figures 5 and 6 ). IVa2, expressed during DNA replication, is implicated in the activation of major late promoter during late-phase infection. 32 Thus, upregulation of IVa2 can be correlated with the overexpression of late-phase transcripts and proteins. Such high levels of viral proteins were likely responsible for the increase in cell death during HDV+HV production, which compromised the volumetric productivity (Figures 2c and d) .
Concomitantly, activation of cell death was more pronounced in HDV+HV-producing cells, in which autophagy was evident in these cells (Figure 8 ). Autophagy, in addition to its role in degradation and recycling of cellular constituents, 40, 41 can act as a form of programmed cell death. 42, 43 Recent studies link autophagy to the main mechanisms for Ad-mediated cell lysis. 35, 36 This type of programmed cell death was therefore more activated during HDV+HV production, which may be implicated in a critical physiological state. Still, autophagy may be necessary for a successful Ad replication. 36 Together, our results are in line with the importance of a balanced autophagy activation to pursue both a sustainable host cell homeostasis and an adequate environment for virus amplification and maturation.
Consistent with the overall increase in viral protein production in HDV+HV-producing cells, more viral capsids (empty plus genome-containing) were obtained when compared with ΔE1 +HV-infected cells (Figure 7a ). This demonstrates that assembly occurred in proportion to the viral protein content ( Figure 6 ). Given the similar number of physical (genome-containing) particles between HDV and ΔE1 infection (Figure 2a ), this also indicates that more empty and/or defective particles were obtained during HDV+HV production. Assembly of Ad particles proceeds packaging: the Ad genome, along with packaging proteins, interacts with structural and non-structural proteins resulting in the formation of a 'procapsid' structure with the viral DNA. 44 Then, the genome is encapsidated. The quantification of DNA-containing particles showed that HDV packaging occurred similarly to control infections (Figure 2a ). Empty capsids and free viral genomes were obtained in all of the assayed productions schemes (Figure 7) . This indicates that a threshold for packaging was obtained, even under higher levels of viral transcripts involved in packaging, namely IVa2 ( Figure 5 ), 33 L1 52/55K, 45 L4 22K 46 and IIIa, 47 as observed during HDV+HV production (data not shown). Together, these observations raise the hypothesis that post-transcriptional events or the levels of host cell factors, such as P-complex, 48 may influence genome packaging in a rate limiting manner.
Following assembly and packaging, Ad undergoes a final maturation step driven by the virus-encoded protease. This process, involving the cleavage of several viral proteins and increased by the presence of two co-factors (C-terminal of pVI and viral double-stranded DNA), renders virus particles infectious. 28, 49 High levels of pVI and protease transcripts were obtained during HDV+HV production ( Figure 5) , however, the low infectious titer of these vectors suggests a defect in capsid maturation. On the other hand, late-phase viral proteins produced earlier may compromise cell homeostasis and the success of virus replication progress. For instance, protease is also responsible for the cleavage of cell cytokeratin system, weakening mechanical integrity of the cell and promoting host cell lysis late in infection. 50 Thus, such high levels of protease earlier (or any late-phase product) may contribute to impair cell integrity in a way that maturation step is not fully accomplished. Taking this into account, we hypothesized a link between cell death/physiological state imposed by HDV infection and impaired virus maturation. To test this possibility, an intracellular environment similar to HDV+HV-producing cells was induced in ΔE1-producing cells. Similar protein levels and cell death profiles to those obtained during HDV production were detected using this strategy (Figure 9 ), consistent with a correlation of cell death with viral protein content. However, the impact of earlier cell death on virus maturation is only partial, because the differences in ΔE1 infectivity (PP:IP ratio) ( Figure 9b ) did not reach the fourfold decrease observed in HDV (Figure 2a ). This suggests that the physiological state of HDV+HV-producing cells was not fully simulated using the increasing HV MOI strategy. In fact, higher levels of autophagosomes were always obtained in HDV+HV-producing cells, even in cells co-infected with ΔE1 and HV at MOI 40 (data not shown), which supports the hypothesis of a HDV-specific interaction with producer cell. In addition, other intrinsic feature of HDV may also be implicated in maturation and viral particles infectivity. The maturation process is thought to be independent of DNA sequence, 27 thus the effect of HDV genome sequence should be ruled out. However, it is not known how viral genome structurally interacts with core proteins, and if that affects viral capsid assembly and subsequent maturation. In the light of these results, the role of stuffer sequence and the clarification of HDV structure would be important to understand any connection with viral particle maturation state. 26 In summary, in HDV+HV-producing cells viral genome replication occurred faster, leading to higher levels of late region proteins. Such high viral protein content was consistent with increased cell death observed during production. Despite similar cell-specific productivities of total HDV and ΔE1 virions, infectious to PPs ratios obtained in HDV were four times lower, indicating lower infectivity. Increased levels of empty capsids and defective particles interfere with the infectious titers. Therefore, factors affecting the maturation process should be involved. For instance, it is likely that the cell physiological state contributed to reduced vectors infectivity. Nevertheless, a particular feature of HDV must be further affecting its maturation, which would fully explain the differences in infectious titers.
This work identifies faster genome replication, viral protein synthesis, higher production of defective particles and lower maturation as bottlenecks in helper-dependent CAV-2 production, highlighting the effect of vector design on the virus replication cycle and virus-cell interaction as an important feature to understand the viral vector productive outcome.
MATERIALS AND METHODS
Cell lines and culture medium MDCK (ECCAC, Nr 84121903) and MDCK-E1-Cre cells 51 were grown in Dulbecco's modified Eagle's medium (Gibco, Paisley, UK) supplemented with 10% (v/v) fetal bovine serum (Gibco). Cells were maintained at 37°C in a humidified atmosphere air containing 5% CO 2 .
Cell concentration and viability were determined by the Trypan blue exclusion method using a 0.1% (v/v) solution prepared in phosphatebuffered saline (PBS) and counting cells in a Fuchs-Rosenthal haemacytometer (Brand, Wertheim, Germany). Vectors CAVGFP, JBΔ5 and HD CAVGFP are vectors derived from CAV-2 strain Toronto A 26/61, GenBank J04368. CAVGFP 2 and HD CAVGFP 7 are E1-deleted (ΔE1) and HD vectors, respectively, and contain a cytomegalovirus-enhanced GFP expression cassette. JBΔ5 is a HV containing loxP flanking the packaging domains and a RSV-lacZ expression cassette. 7 CAVGFP, JBΔ5 and HD CAVGFP viral stocks were prepared and purified by CsCl gradients as described previously. 2, 51 Gene expression analysis To assess gene expression, total RNA was extracted from 1 × 10 6 cells using RNeasy mini kit (Qiagen, Germantown, MD, USA). In infected cells, two rounds of RNA cleaning were performed. For real-time PCR, RPL-22 was Figure 9 . Production of ΔE1 vectors by inducing the intracellular environment obtained in HDV-producing cells at 48 h.p.i. The intracellular environment of HDV+HV-producing cells was induced by co-infecting cells with MOI 5 of ΔE1 and increasing MOIs of HV. (a) Western blot of cell extracts to compare production of viral proteins. Cell extracts were normalized to cell concentration and each lane was loaded with same sample volume. Cell extracts of HDV+HV-producing cells were added as a control to show the level of proteins produced under these conditions. Image corresponds to a single membrane and was processed as described in Figure 6 . chosen as a control gene. Reverse transcription of total RNA was performed according to Transcriptor High Fidelity cDNA Synthesis kit (Roche Applied Science, Mannheim, Germany) protocol for complementary DNA (cDNA) synthesis using 1 μg of total RNA and oligo dT primer for total mRNA reverse transcription. The reverse transcribed cDNA was aliquoted and stored at − 20°C until further processing. SYBR Green I dye chemistry was used to detect the PCR products using LightCycler 480 SYBR Green I Master (Roche Applied Science) according to the manufacturer's instructions using LightCycler 480 Real Time PCR System (Roche Applied Science). cDNA samples were run with a reverse transcription reaction-free control and a sample without cDNA template. The primers used for each target are shown in Supplementary Table S1 .
Viral vectors amplification studies
MDCK-E1-Cre cells were seeded at 1.5 × 10 4 cells cm -2 , infected the day after with medium exchange. Unless stated otherwise, HD CAVGFP production assays were performed using MOI 5 and MOI 1 of HD CAVGFP and JBΔ5, respectively. As control, CAVGFP production assays were performed by co-infecting JBΔ5 under same conditions. Production assays using single infection of JBΔ5 with MOI 1 were also performed to isolate the role of this vector on production kinetics. Intracellular samples were collected using triton (Sigma-Aldrich, St Louis, MO, USA) 0.1% (v/v) in Tris HCl, clarified at 3000 g for 10 min at 4°C and stored at − 85°C until further analysis.
Infectious vectors titration
Quantification of infectious HD CAVGFP and CAVGFP was performed by monitoring the expression of GFP, whereas titration of infectious JBΔ5 vectors was based in lacZ gene expression and β-galactosidase activity as described previously. 51 
Viral genomes and PPs by real-time PCR
Viral genomes were extracted and purified by High Pure Viral Nucleic Acid Kit (Roche Diagnostics, Penzberg, Germany). SYBR Green I dye chemistry was used to detect PCR products using LightCycler system. Quantification was based on the detection of GFP (for HD CAVGFP and CAVGFP) or lacZ (for JBΔ5). Previously purified and quantified plasmids coding for E1-deleted CAV-2 genome, GFP or lacZ were used as standards. To ensure the removal of free viral genomes from samples and accurately quantify viral PPs, a benzonase treatment was performed before DNA extraction by adding 2 μl of benzonase (250 U μl -1 ) (Merck Millipore, Darmstadt, Germany) to the same sample volume and incubating for 1 h at 37°C. Benzonase was inhibited using the proteinase K step of DNA extraction protocol. GFP and lacZ primers are shown in Supplementary Table S1 .
Quantification of assembled capsids
After confirming that virions and empty capsids were quantifiable through Nanoparticle Tracking Analysis (NTA), assembled capsids were titrated using LM10 instrument (NanoSight, Amesbury, UK). Following the manufacturer's instructions, samples were diluted with Dulbecco's PBS to reach a particle concentration suitable for analysis with NTA (1.0 × 10 8 to 2.5 × 10 9 particles ml -1 ). At least two different dilutions were prepared for each sample and analyzed twice. The NanoSight LM10 recorded 60 s sample videos, which were then analyzed with the NTA 2.0 Analytical software release version build 0125 (NanoSight). The NTA software is then able to identify and track individual nanoparticles moving under Brownian motion and the results allow particle size and concentration to be recovered. 52 Cell death analysis Cells were seeded in 24-well plates, infected under the conditions above mentioned and analyzed for necrosis and autophagy at 20 h.p.i. Necrosis was assessed by staining cells with propidium iodide (Sigma-Aldrich). After 20 h.p.i., cells were collected from wells in duplicates, stained with 2 μl of propidium iodide solution (Sigma-Aldrich) in 2 ml final volume, incubated in the dark for 10 min and analyzed by flow cytometry using a CyFlow Space (Partec, Münster, Germany) equipped with a 561 nm yellow laser and 630 ± 22 nm filter. Non-stained and non-infected controls were also analyzed. Autophagy was evaluated through the detection of autophagosomes by immunostaining. Cells grown in coverslips inside wells were fixed in 4% (w/v) paraformaldehyde+4% sucrose (w/v) in PBS, permeabilized with 0.1% (v/v) Triton X-100 solution (Sigma-Aldrich) and processed as described previously. 53 Briefly, after blocking with 0.2% (w/v) fish skin gelatin, samples were incubated with anti-LC3B antibody (Sigma-Aldrich), diluted to 1:100 in 0.125% (w/v) fish skin gelatin+0.1% (v/v) Triton X-100 in PBS. Alexa Fluor 647 Goat Anti-Rabbit IgG (H+L) antibody (Invitrogen, Carlsbad, CA, USA) was used as secondary antibody diluted to 1:500. Cell nuclei were counter stained with ProLong Gold antifade reagent with 4,6-diamidino-2-phenylindole (Invitrogen). Samples were visualized using fluorescence microscopy (DMI6000, Leica Microsystems GmbH, Wetzlar, Germany). Images were processed using the open source ImageJ software (Rasband, WS, ImageJ, U. S. National Institutes of Health, Bethesda, MD, USA, http://imagej.nih.gov/ij/, 1997-2012.). Autophagypositive cells were quantified by counting the number of cells presenting autophagosomes in relation to the number of stained nuclei. Quantifications were performed in two biological replicates, using at least three different sections per replicate.
Western blot analysis
Cell protein extracts were obtained from 1 × 10 6 cells using 500 μl of mammalian protein extraction reagent M-PER (Thermoscientific, Rockford, IL, USA) according to the manufacturer's instructions. Equal volumes of sample were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel according to NuPAGE SDS-PAGE gel system (Invitrogen), and transfered to Hybond-C extra membranes (GE Healthcare, Uppsala, Sweden) using Trans-blot turbo transfer system (Bio-Rad, Hercules, CA, USA). Membranes were blocked with 5% (w/v) dry milk in tris-buffered saline-Tween 20, and probed with polyclonal rabbit anti-CAV-2 primary antibody 54 and anti-β actin abcam8226 (housekeeping control). Both antibodies were diluted to 1:1000. Western blot membrane detection was performed using horseradish peroxidase-linked antibodies and Amersham ECL (GE Healthcare) reagents and protocols.
Nuclei extracts
Cells at 80% confluence in four 150 cm 2 T-flasks were infected and harvested 8 h.p.i. in cold PBS using a cell scraper. The extract from nuclei were prepared by adapting the protocol provided in CelLytic NuCLEAR extraction kit (Sigma-Aldrich). Briefly, cells were centrifuged and suspended in Lysis buffer (5 mM Tris HCl, pH 7.5 with 1 mM MgCl 2 , 1.5 mM CaCl 2 and 1 mM DTT), then cells were let to swell on ice for 15 min and disrupted using a syringe with a narrow-gauge needle (no. 26). After the suspension was centrifuged during 20 min at 11 000 g, and the crude nuclei pellet suspended in extraction buffer (20 mM HEPES pH 7.9, with 1.5 mM MgCl 2 and 0.42 M NaCl, 0.2 mM EDTA, 1 mM DTT and 25% (v/v) glycerol). Finally, 0.1% (v/v) of Triton (Sigma-Aldrich) in Tris HCl was added, the suspended nuclei was agitated for 30 min and centrifuged for 3000 g during 10 min at 4°C. Extracts were stored at − 85°C. Viral genomes were isolated from nuclei extracts using the High Pure Viral Nucleic Acid Kit (Roche diagnostics) and quantified as stated above.
